CJC-1295 and Ipamorelin: What Does the Evidence Show?
CJC-1295 and ipamorelin can stimulate growth hormone signalling. That does not tell us whether taking them together builds muscle, reduces body fat, improves sleep, or speeds recovery in people. The combination has not been tested well enough to make those claims. [1] [2]
The claim being checked
Using CJC-1295 with ipamorelin improves muscle growth, fat loss, recovery, sleep, or healthy ageing in adults.
WhatEvidence.Health verdict: Uncertain
Human studies support a change in hormone levels after each peptide is given separately. They do not establish meaningful benefits from the combination. No reliable comparison shows that adding one to the other produces better health or physique outcomes. [3] [4] [1]
How are these peptides meant to work?
Growth hormone is a natural hormone involved in growth and metabolism. CJC-1295 is designed to stimulate its release through the growth hormone-releasing hormone pathway. Ipamorelin acts through a different receptor involved in growth hormone release. That gives a reason to study the combination, but a plausible mechanism is not proof of a useful result. [1] [2]
Product identity matters. The published CJC-1295 human studies appear to have used a long-acting version with a drug affinity complex (DAC). Evidence from that version cannot automatically be applied to products sold as “CJC-1295 without DAC,” or to an unspecified CJC-1295 and ipamorelin blend. [1]
What the best evidence says
SupportedCJC-1295 with DAC raises growth hormone and insulin-like growth factor 1
Two short, randomised, double-blind, placebo-controlled dose studies in healthy adults found sustained increases in growth hormone and insulin-like growth factor 1 (IGF-1), a hormone influenced by growth hormone. The studies measured hormone levels and drug behaviour. They did not measure whether participants gained muscle, lost fat, slept better, or recovered faster. [3] [1]
SupportedIpamorelin can produce a short growth hormone pulse
A dose-escalation study in healthy men recorded a brief growth hormone response after intravenous ipamorelin. It did not test body composition, sleep, or a combined CJC-1295 treatment. [4]
UncertainA larger ipamorelin trial finished, but its results are not available
A separate phase 2 trial enrolled 320 people after bowel surgery and tested intravenous ipamorelin against placebo. It completed in 2014, but the ClinicalTrials.gov record has no posted results. We cannot tell from that record whether ipamorelin helped, failed to help, or caused harms in this trial. It did not test CJC-1295 or the marketed combination. [7]
UncertainDoes the combination improve muscle, fat loss, sleep, or recovery?
The available hormone studies do not answer this question. The US Food and Drug Administration (FDA) described websites promoting CJC-1295 with ipamorelin, but did not identify clinical outcome evidence establishing those advertised benefits. An untested benefit remains uncertain, even when both ingredients change the same hormone pathway. [1] [2]
What remains uncertain
We do not know whether the combination performs better than either peptide alone for outcomes people can feel or measure. We also cannot assume that results from a short laboratory study apply to repeated injections, different peptide forms, or products with uncertain ingredients. The 320-person ipamorelin study cannot settle these questions because its results are not posted, and it did not test the combination. The absence of a good combination trial is not evidence that it works, and it is not proof that it cannot work. [1] [2] [7]
Safety and regulatory context
In short CJC-1295 DAC studies, reported reactions included injection-site problems, headache, diarrhoea, and flushing or temporary low blood pressure. In an intravenous ipamorelin study after bowel surgery, low potassium and high blood glucose were reported more often with ipamorelin than placebo. Two treated patients died after serious surgical complications; whether ipamorelin contributed was unclear. These studies do not establish the safety of the marketed combination. [1] [2]
Australia’s Therapeutic Goods Administration identifies CJC-1295 products as examples of unapproved peptides. It warns that unapproved products may have uncertain quality, sterility, ingredients and labelling. Online availability or compounding does not mean a product has been evaluated or approved for the advertised benefits. [5]
Key human studies
On mobile: swipe sideways to view all columns.
| Source | What it found | Main limitations |
|---|---|---|
| CJC-1295 study, 2006 [3] Two randomised, blinded, placebo-controlled dose studies; 66 healthy adults across both studies. |
Growth hormone and IGF-1 levels increased after CJC-1295 with DAC. | Short duration; hormone outcomes only; no combination, muscle, fat, sleep, or recovery outcomes. |
| Ipamorelin volunteer study, 1999 [4] Dose escalation; 8 healthy men at each of five infusion levels. |
A short growth hormone response followed intravenous infusion. | Small groups; hormone outcome only; not the marketed injection route or combination. |
| Ipamorelin bowel-surgery trial, 2014 [6] Randomised, double-blind, placebo-controlled; 114 treated participants. |
Time to tolerating a meal was numerically shorter, but the difference was not statistically significant. | Hospital patients after surgery; intravenous treatment; unrelated to wellness or physique outcomes. |
| Ipamorelin trial, NCT01280344 [7] Phase 2; 320 enrolled; completed in 2014. |
No results are posted. Benefit and harms cannot be assessed from the registry record. | Bowel-surgery patients, not a CJC-1295 combination study; unpublished outcome data. |
Bottom line
Changing growth hormone levels is not the same as showing a health benefit. The evidence does not currently establish that CJC-1295 and ipamorelin together improve muscle, fat loss, sleep, recovery, or healthy ageing. Product form and long-term safety remain important unknowns. [1] [2]
Frequently asked questions
Does CJC-1295 with ipamorelin build muscle?
A human hormone response is documented for each peptide separately, but the evidence reviewed here does not establish muscle gain from the combination. [1]
Does the combination help with fat loss?
No controlled human outcome study in this evidence set shows that the combination reduces body fat. Hormone changes alone cannot answer that question. [1] [2]
Is “CJC-1295 without DAC” the same as the form in the published human studies?
No. The published human studies appear to involve CJC-1295 with DAC. Results should not be assumed to apply to a product labelled “without DAC.” [1]
Does a rise in growth hormone prove better sleep or recovery?
No. The studies measuring growth hormone did not show that the combination improves those outcomes. [3] [4]
What happened in the 320-person ipamorelin trial?
The trial completed in 2014, but its ClinicalTrials.gov record has no posted results. It studied bowel recovery after surgery, not CJC-1295 with ipamorelin for muscle, fat loss, sleep, or recovery from exercise. [7]
Does online sale mean these peptides are approved in Australia?
No. The Therapeutic Goods Administration identifies CJC-1295 products among unapproved peptides and warns about uncertain quality and safety. [5]
References
- FDA. CJC-1295-related bulk drug substances assessment, 2024.
- FDA. Ipamorelin-related bulk drug substances assessment, 2024.
- Teichman et al. CJC-1295 hormone-response studies in healthy adults, 2006.
- Ipamorelin pharmacokinetic and hormone-response study in healthy volunteers, 1999.
- Therapeutic Goods Administration. Unapproved peptide products safety advisory, 2026.
- Beck et al. Ipamorelin after bowel resection, randomised trial, 2014.
- ClinicalTrials.gov. Ipamorelin after bowel resection, phase 2 trial NCT01280344, completed 2014; no results posted.
Disclaimer: This article is for general educational information only and is not medical advice. It does not diagnose, treat, or replace care from a qualified health professional. Always speak with a qualified health professional about personal health questions, medicines, pregnancy, medical conditions, or before changing treatment.
